PD-L1 TC ≥ 50% or IC ≥ 10%
1 drugsPredictive biomarker for patient selection in 6 indications
1
Approved Drugs
6
Indications
1
Companies
PD-L1 TC ≥ 50% or IC ≥ 10% is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 6 indications including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing PD-L1 TC ≥ 50% or IC ≥ 10% drugs below.
Search PD-L1 TC ≥ 50% or IC ≥ 10% Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-L1 TC ≥ 50% or IC ≥ 10%
| Drug | Company | Therapeutic Area |
|---|---|---|
| TECENTRIQ HYBREZA | Roche | Oncology |
PD-L1 TC ≥ 50% or IC ≥ 10% Indications
Non-Small Cell Lung Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer